Health Business Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Health Business Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
AMDL
FDA Grants AMDL Clearance to Market the AMDL-ELISA DR-70 FDP Blood Test for Monitoring Colorectal Cancer
July 25th, 2008
AMDL (AMEX:ADL), a leading vertically integrated bio-pharmaceutical company with operations in China and the US, announced the US Food and Drug Administration (FDA) has issued a letter of substantial equivalence to an existing predicate device and granted clearance to market the AMDL-ELISA DR-70(R) (FDP) as a safe and effective blood test for monitoring patients who have been previously diagnosed with colorectal cancer (CRC). According to US-based medical research group Kalorama Research, the world market for in vitro diagnostic (IVD) tests for cancer is growing at nearly 11% annually and could reach nearly $8 billion by the end of 2012 (Kalorama Research Group: 2008)....
Source: Health Business Week (2008-07-25)
|
